MATHEW MCCARTHY: Open Payments
NPI 1306917570 · KENOSHA, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$928 in 41 payments from 14 companies in 2025. Trend: 2023 $163 · 2024 $929 · 2025 $928
Food & beverage: $928
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 11 | $248 |
| Vanda Pharmaceuticals Inc. | 4 | $95 |
| Teva Pharmaceuticals USA, Inc. | 3 | $85 |
| Alkermes, Inc. | 3 | $84 |
| ABBVIE INC. | 4 | $84 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| E.R. Squibb & Sons, L.L.C. | 3 | $58 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| Janssen Pharmaceuticals, Inc | 2 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
Products named: INGREZZA, FANAPT, AUSTEDO XR, ARISTADA, VRAYLAR, REXULTI, Auvelity, INVEGA SUSTENNA.
Industry payments across WI — which companies pay providers there.
